Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4998494 | 0.91 | PARP1 (0.74) | PARP1 | |
| SCHEMBL17082607 | 0.89 | PARP1 (0.72) | PARP1 | |
| SCHEMBL5002092 | 0.83 | PARP1 (1.00) | PARP1 | |
| SCHEMBL5003154 | 0.83 | PARP1 (0.74) | PARP1 | |
| SCHEMBL5005691 | 0.82 | PARP1 (0.85) | PARP1 | |
| SCHEMBL29369918 | 0.82 | PARP1 (1.00) | PARP1 | |
| SCHEMBL5002723 | 0.82 | PARP1 (1.00) | PARP1 | |
| SCHEMBL5002204 | 0.82 | PARP1 (0.81) | PARP1 | |
| SCHEMBL5002142 | 0.81 | PARP1 (0.75) | PARP1 | |
| SCHEMBL5002417 | 0.81 | PARP1 (1.00) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20150290185-A1 | Polymeric Compound Having Camptothecin Compound And Anti-Cancer Effect Enhancer Bound Thereto, And Use of Same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2015-10-15 | — | — | US | disclosed |
| US-7429578-B2 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | AGOURON PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429578-B2 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | AGOURON PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429578-B2 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | AGOURON PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20060009517-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | AGOURON PHARMACEUTICALS, INC. | 2006-01-12 | — | — | US | disclosed |
| US-6977298-B2 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | Agouron Pharmacetucals, Inc. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050085460-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | AGOURON PHARMACEUTICALS, INC. | 2005-04-21 | — | — | US | disclosed |
| EP-1140936-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMA (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030078254-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | WEBBER STEPHEN EVAN (US) | 2003-04-24 | — | — | US | disclosed |
| US-6495541-B1 | POTENTIATION OF ANTICANCER THERAPIES AND INHIBITION OF NEUROTOXICITY CONSEQUENT TO STROKE, HEAD TRAUMA, AND NEURO-DEGENERATIVE DISEASES; SUCH AS 2-BROMO-3,4-DIHYDROPYRROLO-(4,3,2-DE)ISOGUINOLIN-5-ONE | AGOURON PHARMACEUTICALS, INC. | 2002-12-17 | — | — | US | disclosed |
| EP-1140936-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042040-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009517-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | PARP1, PARP2, PARP11 | PARP1 1/4885 |
| US-20050085460-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | PARP1, PARP2, PARP11 | PARP1 1/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | PARP1 2/4885 |
| US-20030078254-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | PARP1, PARP11, PARP2 | PARP1 1/4885 |
| US-20150290185-A1 | Polymeric Compound Having Camptothecin Compound And Anti-Cancer Effect Enhancer Bound Thereto, And Use of Same | PARP1, PARP2, PARP4 | PARP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.